{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T11:04:00Z","timestamp":1785927840071,"version":"3.56.0"},"reference-count":95,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2023,2,10]],"date-time":"2023-02-10T00:00:00Z","timestamp":1675987200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomolecules"],"abstract":"<jats:p>Cystic fibrosis (CF) is a high-prevalence disease characterized by significant lung remodeling, responsible for high morbidity and mortality worldwide. The lung structural changes are partly due to proteolytic activity associated with inflammatory cells such as neutrophils and macrophages. Matrix metalloproteases (MMPs) are the major proteases involved in CF, and recent literature data focused on their potential role in the pathogenesis of the disease. In fact, an imbalance of proteases and antiproteases was observed in CF patients, resulting in dysfunction of protease activity and loss of lung homeostasis. Currently, many steps forward have been moved in the field of pharmacological treatment with the recent introduction of triple-combination therapy targeting the CFTR channel. Despite CFTR modulator therapy potentially being effective in up to 90% of patients with CF, there are still patients who are not eligible for the available therapies. Here, we introduce experimental drugs to provide updates on therapy evolution regarding a proportion of CF non-responder patients to current treatment, and we summarize the role of MMPs in pathogenesis and as future therapeutic targets of CF.<\/jats:p>","DOI":"10.3390\/biom13020350","type":"journal-article","created":{"date-parts":[[2023,2,13]],"date-time":"2023-02-13T03:28:46Z","timestamp":1676258926000},"page":"350","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["The Role of MMPs in the Era of CFTR Modulators: An Additional Target for Cystic Fibrosis Patients?"],"prefix":"10.3390","volume":"13","author":[{"given":"Renata","family":"Esposito","sequence":"first","affiliation":[{"name":"Department of Environmental Biological and Pharmaceutical Sciences and Technologies, University of Campania \u201cLuigi Vanvitelli\u201d, 81100 Caserta, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davida","family":"Mirra","sequence":"additional","affiliation":[{"name":"Department of Environmental Biological and Pharmaceutical Sciences and Technologies, University of Campania \u201cLuigi Vanvitelli\u201d, 81100 Caserta, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1906-5109","authenticated-orcid":false,"given":"Giuseppe","family":"Spaziano","sequence":"additional","affiliation":[{"name":"Department of Environmental Biological and Pharmaceutical Sciences and Technologies, University of Campania \u201cLuigi Vanvitelli\u201d, 81100 Caserta, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Panico","sequence":"additional","affiliation":[{"name":"Department of Environmental Biological and Pharmaceutical Sciences and Technologies, University of Campania \u201cLuigi Vanvitelli\u201d, 81100 Caserta, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0858-7902","authenticated-orcid":false,"given":"Luca","family":"Gallelli","sequence":"additional","affiliation":[{"name":"Department of Health Sciences, University \u201cMagna Graecia\u201d of Catanzaro, 88100 Catanzaro, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"D\u2019Agostino","sequence":"additional","affiliation":[{"name":"Department of Environmental Biological and Pharmaceutical Sciences and Technologies, University of Campania \u201cLuigi Vanvitelli\u201d, 81100 Caserta, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,2,10]]},"reference":[{"key":"ref_1","first-page":"1","article-title":"Gruppo di lavoro RIFC. Registro italiano Fibrosi Cistica (RIFC). Rapporto 2019-2020 [Italian Cystic Fibrosis Registry (ICFR). Report 2019-2020]","volume":"46","author":"Campagna","year":"2022","journal-title":"Epidemiol. Prev."},{"key":"ref_2","unstructured":"Cystic Fibrosis Foundation (2020, August 14). 2018 Patient Registry: Annual Data Report. Available online: https:\/\/www.cff.org\/sites\/default\/files\/2021-11\/Patient-Registry-Annual-Data-Report.pdf."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1016\/S0140-6736(09)60327-5","article-title":"Cystic fibrosis","volume":"373","author":"Freedman","year":"2009","journal-title":"Lancet"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1080\/19336950.2018.1502585","article-title":"Cystic fibrosis transmembrane conductance regulator (CFTR): Making an ion channel out of an active transporter structure","volume":"12","author":"Linsdell","year":"2018","journal-title":"Channels"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1111\/j.1476-5381.2010.01137.x","article-title":"New horizons in the treatment of cystic fibrosis","volume":"163","author":"Cuthbert","year":"2011","journal-title":"Br. J. Pharmacol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e37","DOI":"10.1016\/S2213-2600(16)30188-6","article-title":"Classification of CFTR mutation classes","volume":"4","author":"Marson","year":"2016","journal-title":"Lancet Respir. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1091\/mbc.e14-04-0935","article-title":"From CFTR biology toward combinatorial pharmacotherapy: Expanded classification of cystic fibrosis mutations","volume":"27","author":"Veit","year":"2016","journal-title":"Mol. Biol. Cell"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1136\/thoraxjnl-2015-207588","article-title":"Airway surface liquid homeostasis in cystic fibrosis: Pathophysiology and therapeutic targets","volume":"71","author":"Haq","year":"2016","journal-title":"Thorax"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1002\/ppul.24129","article-title":"Inflammation in cystic fibrosis: An update","volume":"53","author":"Roesch","year":"2018","journal-title":"Pediatr. Pulmonol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1136\/thx.2006.074641","article-title":"Airway remodelling in children with cystic fibrosis","volume":"62","author":"Hilliard","year":"2007","journal-title":"Thorax"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1111\/apa.15155","article-title":"Cystic fibrosis in the year 2020: A disease with a new face","volume":"109","year":"2020","journal-title":"Acta Paediatr."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1001\/jama.293.5.581","article-title":"Longitudinal development of mucoid Pseudomonas aeruginosa infection and lung disease progression in children with cystic fibrosis","volume":"293","author":"Li","year":"2005","journal-title":"JAMA"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1164\/rccm.201901-0145OC","article-title":"Correlating Cystic Fibrosis Transmembrane Conductance Regulator Function with Clinical Features to Inform Precision Treatment of Cystic Fibrosis","volume":"199","author":"McCague","year":"2019","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.jcf.2012.07.003","article-title":"Innate immunity in cystic fibrosis lung disease","volume":"11","author":"Hartl","year":"2012","journal-title":"J. Cyst. Fibros."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s12950-017-0176-1","article-title":"Neutrophil extracellular traps and the dysfunctional innate immune response of cystic fibrosis lung disease: A review","volume":"14","author":"Law","year":"2017","journal-title":"J. Inflamm."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1055\/s-0039-1694021","article-title":"Cystic Fibrosis: Pathophysiology of Lung Disease","volume":"40","author":"Bergeron","year":"2019","journal-title":"Semin. Respir. Crit. Care Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1600903","DOI":"10.1183\/13993003.00903-2016","article-title":"Hypoxia and sterile inflammation in cystic fibrosis airways: Mechanisms and potential therapies","volume":"49","author":"Montgomery","year":"2017","journal-title":"Eur Respir. J."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1097\/MCP.0b013e32834b8c04","article-title":"Pulmonary exacerbations in cystic fibrosis","volume":"17","author":"Stenbit","year":"2011","journal-title":"Curr. Opin. Pulm. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1136\/thx.2009.134106","article-title":"Airway remodelling and its relationship to inflammation in cystic fibrosis","volume":"66","author":"Regamey","year":"2011","journal-title":"Thorax"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1056\/NEJMra1300109","article-title":"Origins of cystic fibrosis lung disease","volume":"372","author":"Stoltz","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"107839","DOI":"10.1016\/j.pharmthera.2021.107839","article-title":"Therapeutic targets in lung tissue remodelling and fibrosis","volume":"225","author":"Liu","year":"2021","journal-title":"Pharmacol. Ther."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.chest.2018.04.036","article-title":"Ion Channel Modulators in Cystic Fibrosis","volume":"154","author":"Gentzsch","year":"2018","journal-title":"Chest"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1177\/1753465816680573","article-title":"Best practices in the treatment of early cystic fibrosis lung disease","volume":"11","author":"Proesmans","year":"2017","journal-title":"Ther. Adv. Respir. Dis."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1056\/NEJMoa1105185","article-title":"A CFTR potentiator in patients with cystic fibrosis and the G551D mutation","volume":"365","author":"Ramsey","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.1007\/s00431-021-04168-y","article-title":"A new era for people with cystic fibrosis","volume":"180","author":"Bierlaagh","year":"2021","journal-title":"Eur. J. Pediatr."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1164\/rccm.201710-2046LE","article-title":"GOAL Investigators of the Cystic Fibrosis Foundation Therapeutics Development Network. Ivacaftor-treated Patients with Cystic Fibrosis Derive Long-Term Benefit Despite No Short-Term Clinical Improvement","volume":"197","author":"Heltshe","year":"2018","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"19810","DOI":"10.1038\/s41598-021-99184-1","article-title":"Elexacaftor is a CFTR potentiator and acts synergistically with ivacaftor during acute and chronic treatment","volume":"11","author":"Shaughnessy","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_29","first-page":"00082","article-title":"Clinical development of triple-combination CFTR modulators for cystic fibrosis patients with one or two F508del alleles","volume":"5","author":"Mall","year":"2019","journal-title":"ERJ Open Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.cell.2019.12.032","article-title":"A Therapy for Most with Cystic Fibrosis","volume":"180","author":"Bear","year":"2020","journal-title":"Cell"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1183\/09031936.00121611","article-title":"Series \u201cmatrix metalloproteinases in lung health and disease\u201d: Matrix metalloproteinases in COPD","volume":"39","author":"Churg","year":"2012","journal-title":"Eur. Respir. J."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Chuli\u00e1-Peris, L., Carreres-Rey, C., Gabasa, M., Alcaraz, J., Carretero, J., and Pereda, J. (2022). Matrix Metalloproteinases and Their Inhibitors in Pulmonary Fibrosis: EMMPRIN\/CD147 Comes into Play. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23136894"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Serra, R. (2022). Matrix Metalloproteinases in Health and Disease 2.0. Biomolecules, 12.","DOI":"10.3390\/biom12091190"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Oriano, M., Amati, F., Gramegna, A., De Soyza, A., Mantero, M., Sibila, O., Chotirmall, S.H., Voza, A., Marchisio, P., and Blasi, F. (2021). Protease-Antiprotease Imbalance in Bronchiectasis. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22115996"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1183\/09031936.00173210","article-title":"The role of matrix metalloproteinases in cystic fibrosis lung disease","volume":"38","author":"Gaggar","year":"2011","journal-title":"Eur. Respir. J."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1152\/physrev.00022.2006","article-title":"Matrix metalloproteinases in lung: Multiple, multifarious, and multifaceted","volume":"87","author":"Greenlee","year":"2007","journal-title":"Physiol. Rev."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/nrm2125","article-title":"Matrix metalloproteinases and the regulation of tissue remodelling","volume":"8","author":"Ewald","year":"2007","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"McKelvey, M.C., Brown, R., Ryan, S., Mall, M.A., Weldon, S., and Taggart, C.C. (2021). Proteases, Mucus, and Mucosal Immunity in Chronic Lung Disease. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22095018"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"155","DOI":"10.3390\/pathophysiology28010011","article-title":"Pathophysiology of Lung Disease and Wound Repair in Cystic Fibrosis","volume":"28","author":"Conese","year":"2021","journal-title":"Pathophysiology"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1501200","DOI":"10.1183\/13993003.01200-2015","article-title":"Protean proteases: At the cutting edge of lung diseases","volume":"49","author":"Taggart","year":"2017","journal-title":"Eur. Respir. J."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1136\/thorax.57.11.930","article-title":"Matrix metalloproteases in BAL fluid of patients with cystic fibrosis and their modulation by treatment with dornase alpha","volume":"57","author":"Ratjen","year":"2002","journal-title":"Thorax"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.matbio.2015.02.007","article-title":"Extracellular regulation of metalloproteinases","volume":"44\u201346","author":"Yamamoto","year":"2015","journal-title":"Matrix Biol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1056\/NEJMoa1301725","article-title":"Risk factors for bronchiectasis in children with cystic fibrosis","volume":"368","author":"Sly","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1002\/path.1400","article-title":"Extracellular matrix remodelling: The role of matrix metalloproteinases","volume":"200","author":"Stamenkovic","year":"2003","journal-title":"J. Pathol."},{"key":"ref_45","first-page":"1","article-title":"Airway inflammatory markers in individuals with cystic fibrosis and non-cystic fibrosis bronchiectasis","volume":"6","author":"Bergin","year":"2013","journal-title":"J. Inflamm. Res."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"L96","DOI":"10.1152\/ajplung.00492.2006","article-title":"Matrix metalloprotease-9 dysregulation in lower airway secretions of cystic fibrosis patients","volume":"293","author":"Gaggar","year":"2007","journal-title":"Am. J. Physiol. Lung Cell Mol. Physiol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1002\/ppul.20165","article-title":"Induced sputum matrix metalloproteinase-9 correlates with lung function and airway inflammation in children with cystic fibrosis","volume":"39","author":"Sagel","year":"2005","journal-title":"Pediatr. Pulmonol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1080\/019021490944232","article-title":"Matrix metalloproteinase-2 (MMP-2) and MMP-9 in pulmonary pathology","volume":"31","author":"Chakrabarti","year":"2005","journal-title":"Exp. Lung Res."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1183\/09031936.00212114","article-title":"Australian Respiratory Early Surveillance Team for Cystic Fibrosis (AREST CF). Matrix metalloproteinase activation by free neutrophil elastase contributes to bronchiectasis progression in early cystic fibrosis","volume":"46","author":"Garratt","year":"2015","journal-title":"Eur. Respir. J."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1183\/09031936.00027411","article-title":"A therapeutic role for matrix metalloproteinase inhibitors in lung diseases?","volume":"38","author":"Vandenbroucke","year":"2011","journal-title":"Eur. Respir. J."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1182\/blood.V96.8.2673","article-title":"Neutrophil gelatinase B potentiates interleukin-8 tenfold by aminoterminal processing, whereas it degrades CTAP-III, PF-4, and GRO-alpha and leaves RANTES and MCP-2 intact","volume":"96","author":"Proost","year":"2000","journal-title":"Blood"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.jcf.2014.01.010","article-title":"An observational study of matrix metalloproteinase (MMP)-9 in cystic fibrosis","volume":"13","author":"Devereux","year":"2014","journal-title":"J. Cyst. Fibros."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Bratcher, P.E., Weathington, N.M., Nick, H.J., Jackson, P.L., Snelgrove, R.J., and Gaggar, A. (2012). MMP-9 cleaves SP-D and abrogates its innate immune functions in vitro. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0041881"},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Wagner, C., Bal\u00e1zs, A., Schatterny, J., Zhou-Suckow, Z., Duerr, J., Schultz, C., and Mall, M.A. (2022). Genetic Deletion of Mmp9 Does Not Reduce Airway Inflammation and Structural Lung Damage in Mice with Cystic Fibrosis-like Lung Disease. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms232113405"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1093\/ecco-jcc\/jjab064","article-title":"Matrix Metalloproteinase MMP-12 Promotes Macrophage Transmigration Across Intestinal Epithelial Tight Junctions and Increases Severity of Experimental Colitis","volume":"15","author":"Nighot","year":"2021","journal-title":"J. Crohns. Colitis."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s40348-016-0053-7","article-title":"Neutrophil elastase and matrix metalloproteinase 12 in cystic fibrosis lung disease","volume":"3","author":"Wagner","year":"2016","journal-title":"Mol. Cell Pediatr."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"L325","DOI":"10.1152\/ajplung.00294.2014","article-title":"ADAM-family metalloproteinases in lung inflammation: Potential therapeutic targets","volume":"308","author":"Dreymueller","year":"2015","journal-title":"Am. J. Physiol. Lung Cell Mol. Physiol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1165\/rcmb.2013-0407OC","article-title":"Airway mucus obstruction triggers macrophage activation and matrix metalloproteinase 12-dependent emphysema","volume":"51","author":"Trojanek","year":"2014","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1096\/fj.06-5898fje","article-title":"Matrix metalloproteinase 2 and basement membrane integrity: A unifying mechanism for progressive renal injury","volume":"20","author":"Cheng","year":"2006","journal-title":"FASEB J."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1139\/y99-044","article-title":"Inhibition of matrix metalloproteinase MMP-2 activates chloride current in human airway epithelial cells","volume":"77","author":"Duszyk","year":"1999","journal-title":"Can. J. Physiol. Pharmacol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.jcf.2009.06.001","article-title":"Serum matrix metalloproteinases in adult CF patients: Relation to pulmonary exacerbation","volume":"8","author":"Roderfeld","year":"2009","journal-title":"J. Cyst. Fibros."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1089\/wound.2014.0581","article-title":"Metalloproteinases and Wound Healing","volume":"4","author":"Caley","year":"2015","journal-title":"Adv. Wound Care"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"6292","DOI":"10.1073\/pnas.092134099","article-title":"Gene expression analysis reveals matrilysin as a key regulator of pulmonary fibrosis in mice and humans","volume":"99","author":"Zuo","year":"2002","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Rosas, I.O., Richards, T.J., Konishi, K., Zhang, Y., Gibson, K., Lokshin, A.E., Lindell, K.O., Cisneros, J., Macdonald, S.D., and Pardo, A. (2008). MMP1 and MMP7 as potential peripheral blood biomarkers in idiopathic pulmonary fibrosis. PLoS Med., 5.","DOI":"10.1371\/journal.pmed.0050093"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.cytogfr.2006.04.001","article-title":"Matrix metalloproteinase-8: Cleavage can be decisive","volume":"17","author":"Libert","year":"2006","journal-title":"Cytokine Growth Factor Rev."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1080\/14728214.2022.2092612","article-title":"Emerging medicines to improve the basic defect in cystic fibrosis","volume":"27","author":"Fajac","year":"2022","journal-title":"Expert Opin. Emerg. Drugs"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1177\/2472555217729790","article-title":"Use of a High-Throughput Phenotypic Screening Strategy to Identify Amplifiers, a Novel Pharmacological Class of Small Molecules That Exhibit Functional Synergy with Potentiators and Correctors","volume":"23","author":"Giuliano","year":"2018","journal-title":"SLAS Discov."},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Bengtson, C., Silswal, N., Baumlin, N., Yoshida, M., Dennis, J., Yerrathota, S., Kim, M., and Salathe, M. (2022). The CFTR Amplifier Nesolicaftor Rescues TGF-\u03b21 Inhibition of Modulator-Corrected F508del CFTR Function. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms231810956"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"6636","DOI":"10.1016\/j.bmcl.2012.08.107","article-title":"Identification of pyrimidine derivatives as hSMG-1 inhibitors","volume":"22","author":"Gopalsamy","year":"2012","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"McHugh, D.R., Cotton, C.U., and Hodges, C.A. (2020). Synergy between Readthrough and Nonsense Mediated Decay Inhibition in a Murine Model of Cystic Fibrosis Nonsense Mutations. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22010344"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1080\/13543784.2020.1828862","article-title":"ELX-02: An investigational read-through agent for the treatment of nonsense mutation-related genetic disease","volume":"29","author":"Kerem","year":"2020","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1002\/cpdd.647","article-title":"Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses of ELX-02, a Potential Treatment for Genetic Disorders Caused by Nonsense Mutations, in Healthy Volunteers","volume":"8","author":"Leubitz","year":"2019","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1015926","DOI":"10.3389\/fphar.2022.1015926","article-title":"Gene therapy for cystic fibrosis: Challenges and prospects","volume":"13","author":"Sui","year":"2022","journal-title":"Front. Pharmacol."},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Maule, G., Arosio, D., and Cereseto, A. (2020). Gene Therapy for Cystic Fibrosis: Progress and Challenges of Genome Editing. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21113903"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1056\/NEJMra1705346","article-title":"Treating Disease at the RNA Level with Oligonucleotides","volume":"380","author":"Levin","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1186\/s12967-021-03099-4","article-title":"Gene therapy for cystic fibrosis: New tools for precision medicine","volume":"19","author":"Lee","year":"2021","journal-title":"J. Transl. Med."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1038\/nrd4390","article-title":"Is there new hope for therapeutic matrix metalloproteinase inhibition?","volume":"13","author":"Vandenbroucke","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1038\/mt.2016.2","article-title":"Development and Validation of a Small Single-domain Antibody That Effectively Inhibits Matrix Metalloproteinase 8","volume":"24","author":"Demeestere","year":"2016","journal-title":"Mol. Ther."},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Juric, V., O\u2019Sullivan, C., Stefanutti, E., Kovalenko, M., Greenstein, A., Barry-Hamilton, V., Mikaelian, I., Degenhardt, J., Yue, P., and Smith, V. (2018). MMP-9 inhibition promotes anti-tumor immunity through disruption of biochemical and physical barriers to T-cell trafficking to tumors. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0207255"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1002\/ppul.23713","article-title":"Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: II. Cephalosporins and penicillins update","volume":"52","author":"Zobell","year":"2017","journal-title":"Pediatr. Pulmonol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"2990","DOI":"10.1002\/ppul.24945","article-title":"Combining bacteriophages with cefiderocol and meropenem\/vaborbactam to treat a pan-drug resistant Achromobacter species infection in a pediatric cystic fibrosis patient","volume":"55","author":"Gainey","year":"2020","journal-title":"Pediatr. Pulmonol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"e1754","DOI":"10.1093\/cid\/ciaa1847","article-title":"Cefiderocol for the Treatment of Adult and Pediatric Patients with Cystic Fibrosis and Achromobacter xylosoxidans Infections","volume":"73","author":"Warner","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1601102","DOI":"10.1183\/13993003.01102-2016","article-title":"Doxycycline improves clinical outcomes during cystic fibrosis exacerbations","volume":"49","author":"Xu","year":"2017","journal-title":"Eur. Respir. J."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1177\/08959374980120010301","article-title":"Inhibition of MMP synthesis by doxycycline and chemically modified tetracyclines (CMTs) in human endothelial cells","volume":"12","author":"Hanemaaijer","year":"1998","journal-title":"Adv. Dent. Res."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1006\/exer.2001.1054","article-title":"Regulation of MMP-9 production by human corneal epithelial cells","volume":"73","author":"Li","year":"2001","journal-title":"Exp. Eye Res."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"626530","DOI":"10.1155\/2015\/626530","article-title":"Changes of Proteases, Antiproteases, and Pathogens in Cystic Fibrosis Patients\u2019 Upper and Lower Airways after IV-Antibiotic Therapy","volume":"2015","author":"Hentschel","year":"2015","journal-title":"Mediators Inflamm."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1001\/jama.290.13.1749","article-title":"Macrolide Study Group. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: A randomized controlled trial","volume":"290","author":"Saiman","year":"2003","journal-title":"JAMA"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1378\/chest.12-0628","article-title":"Effect of azithromycin on systemic markers of inflammation in patients with cystic fibrosis uninfected with Pseudomonas aeru-ginosa","volume":"142","author":"Ratjen","year":"2012","journal-title":"Chest"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1164\/rccm.201906-1190PP","article-title":"Targeting Proteases in Cystic Fibrosis Lung Disease. Paradigms, Progress, and Potential","volume":"201","author":"McKelvey","year":"2020","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"947359","DOI":"10.3389\/fimmu.2022.947359","article-title":"Divergent dynamics of inflammatory mediators and multiplex PCRs during airway infection in cystic fibrosis patients and healthy controls: Serial upper airway sampling by nasal lavage","volume":"13","author":"Erdmann","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"Terlizzi, V., Parisi, G.F., Ferrari, B., Castellani, C., Manti, S., Leonardi, S., and Taccetti, G. (2022). Effect of Dornase Alfa on the Lung Clearance Index in Children with Cystic Fibrosis: A Lesson from a Case Series. Children, 9.","DOI":"10.3390\/children9111625"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s13052-022-01331-5","article-title":"Dornase alfa in Cystic Fibrosis: Indications, comparative studies and effects on lung clearance index","volume":"48","author":"Terlizzi","year":"2022","journal-title":"Ital. J. Pediatr."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1007\/s13258-019-00836-4","article-title":"Human epididymis protein 4 (HE4) protects against cystic pulmonary fibrosis associated-inflammation through inhibition of NF-\u03baB and MAPK signaling","volume":"41","author":"Wang","year":"2019","journal-title":"Genes Genom."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1096\/fj.201901950R","article-title":"Hypoxia-induced HE4 in tubular epithelial cells promotes extracellular matrix accumulation and renal fibrosis via NF-\u039ab","volume":"34","author":"Zhang","year":"2020","journal-title":"FASEB J."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"592184","DOI":"10.3389\/fphar.2021.592184","article-title":"Enhanced Expression of Human Epididymis Protein 4 (HE4) Reflecting Pro-Inflammatory Status Is Regulated by CFTR in Cystic Fibrosis Bronchial Epithelial Cells","volume":"12","author":"Bene","year":"2021","journal-title":"Front. Pharmacol."}],"container-title":["Biomolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2218-273X\/13\/2\/350\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:30:44Z","timestamp":1760121044000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2218-273X\/13\/2\/350"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,10]]},"references-count":95,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,2]]}},"alternative-id":["biom13020350"],"URL":"https:\/\/doi.org\/10.3390\/biom13020350","relation":{},"ISSN":["2218-273X"],"issn-type":[{"value":"2218-273X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,10]]}}}